Fig. 5
Enhanced recruitment of TET2 to Fgf21 promoter in Wy-offspring at D16. a Hepatic Tet1, Tet2, Tet3, Dnmt3a, and Dnmt3b mRNA expression in mice from D2 to 14W (n = 4–8 per group, statistics by one-way ANOVA with Tukey’s multiple comparison test). Data are expressed as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; N.S., not significant vs. D16. b ChIP assays at D16 with the indicated antibodies. Primers amplifying the region of −106 to +21 bp were used for ChIP-qPCR analysis (Fig. 4a) (n = 4–8 per group, statistics by unpaired Student’s t-test). Data are expressed as mean ± SEM. *P < 0.05; N.S., not significant vs. Veh-offspring. c ChIP assays at 6W for TET2 in mice treated with Wy (Wy-mice) or DMSO (Veh-mice) from 4W to 6W (Fig. 3b) (n = 4 per group, statistics by unpaired Student’s t-test). Data are expressed as mean ± SEM. N.S., not significant vs. Veh-mice
